Dupixent's status as a pipeline in a product has been further cemented by positive data in patients with prurigo nodularis, the sixth disease that Sanofi's blockbuster has succeeded in at Phase III.
Sanofi and partner Regeneron Pharmaceuticals, Inc. have announced results from the Phase III PRIME2 trial evaluating Dupixent (dupilumab) in...